ID: ALA5190846

Max Phase: Preclinical

Molecular Formula: C17H13NO3

Molecular Weight: 279.30

Representations

Canonical SMILES:  Cc1cccc(-c2onc3ccc(/C=C/C(=O)O)cc23)c1

Standard InChI:  InChI=1S/C17H13NO3/c1-11-3-2-4-13(9-11)17-14-10-12(6-8-16(19)20)5-7-15(14)18-21-17/h2-10H,1H3,(H,19,20)/b8-6+

Standard InChI Key:  WMRZQTYUUQFREP-SOFGYWHQSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 279.30

Molecular Weight (Monoisotopic): 279.0895

AlogP: 3.90

#Rotatable Bonds: 3

Polar Surface Area: 63.33

Molecular Species: ACID

HBA: 3

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.99

CX Basic pKa: 0.00

CX LogP: 3.96

CX LogD: 0.79

Aromatic Rings: 3

Heavy Atoms: 21

QED Weighted: 0.74

Np Likeness Score: -0.65

References

1. Zhou Y, Mukherjee S, Huang D, Chakraborty M, Gu C, Zong G, Stashko MA, Pearce KH, Shears SB, Chakraborty A, Wang H, Wang X..  (2022)  Development of Novel IP6K Inhibitors for the Treatment of Obesity and Obesity-Induced Metabolic Dysfunctions.,  65  (9.0): [PMID:35467861] [10.1021/acs.jmedchem.2c00220]

Source

Source(1):

• Scientific Literature